Imaavy nipocalimab

Drug Class

Neonatal Fc receptor (FcRn) blocker

Mechanism

Nipocalimab binds to the neonatal Fc receptor (FcRn) and blocks its interaction with immunoglobulin G (IgG), accelerating the clearance of pathogenic IgG autoantibodies.

Approved Indication

Treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients (12 years and older) who are anti-AChR or anti-MuSK antibody positive.

What This Means For Patients

Imaavy is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2025) — Sources
• EMA — Approved (2025) — Sources

Pivotal Clinical Evidence

• Vivacity-MG3 — Antozzi et al., Lancet Neurol 2025 (NCT04951622) — Sources

Sources

• https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-nipocalimab-fda-approval-generalized-myasthenia-gravis
• https://www.ema.europa.eu/en/medicines/human/EPAR/imaavy
• https://doi.org/10.1016/S1474-4422(24)00498-8